The intestinal barrier functions as a critical interface between the external environment and the host’s internal milieu, primarily maintained by a complex polysaccharide layer called mucin. Mucin is integral to protecting the gut lining from bacterial invasion and other environmental insults. Disruptions to this barrier are increasingly implicated in the pathogenesis of IBD, where an aberrant immune response to altered microbial communities accelerates chronic inflammation. Dr. Kolodkin-Gal’s laboratory has previously demonstrated that subtle, specific changes in the chemical composition and physical properties of mucin serve as biomarkers of microbial interference, heralding the early stages of intestinal inflammation and disease progression.

What distinguishes this research is its innovative methodological approach, which ambitiously seeks to engineer a “mucin-on-a-chip”—a microfluidic platform that recapitulates the biochemical physiology and mechanical dynamics of the intestinal mucosal surface. This organ-on-a-chip technology is designed to model the complex microenvironment of the gastrointestinal tract with unprecedented precision, allowing researchers to observe in real-time how bacterial strains disrupt mucosal integrity. This synthetic biology tool harbors immense potential to unravel multifaceted host-microbe interactions that are otherwise obscured in traditional in vivo or ex vivo studies, enabling mechanistic insights at molecular and cellular levels.

The development of this mucin-on-a-chip is poised to represent a conceptual paradigm shift in the study and treatment of chronic inflammatory gastrointestinal conditions. Rather than merely managing symptoms pharmacologically, this platform could enable the design of targeted therapeutic interventions that modulate specific bacterial communities implicated in disease pathology. The hypothesis that gut bacterial consortia act as drivers rather than mere passengers in chronic inflammation challenges conventional thinking and opens avenues for microbiome-based precision medicine, where sculpting microbial populations could restore barrier function and immune homeostasis.

Further amplifying the potential impact of the project, Dr. Kolodkin-Gal’s team is collaborating with distinguished experts in complementary fields. Co-investigators Prof. Hadar Ben-Yoav from Ben-Gurion University and Prof. Thomas Wood of Penn State University bring critical expertise in mucosal biology and microbial ecology, respectively. This multidisciplinary partnership ensures a robust integration of synthetic biology, bioengineering, microbiology, and clinical relevance, which is essential for translating laboratory findings into therapeutic innovation.

Inflammatory bowel disease is a notoriously complex condition characterized by an interplay between genetic predisposition, immune dysregulation, and environmental factors, including the microbiome. The precise roles of invading bacterial strains have eluded definitive characterization due to the complexity of microbial interactions and the difficulty in modeling dynamic mucosal environments. By employing the mucin-on-a-chip, the research team anticipates delineating how pathogen-associated molecular patterns and bacterial secreted metabolites alter mucin chemistry and subsequently, barrier permeability and immune activation.

This approach represents a leap forward beyond conventional in vitro cell cultures or animal models, which lack the physiological and mechanical fidelity of the human gastrointestinal tract. The microfluidic device will incorporate controlled flows, mucin layering, and bacterial colonization patterns to simulate the realistic spatiotemporal heterogeneity of the intestinal interface. Monitoring how invasive bacteria modify mucin’s glycosylation patterns and viscosity, and how these alterations translate to barrier dysfunction, will generate critical data on the initial steps of mucosal breach and disease amplification.

Moreover, the insights gained from this platform are expected to facilitate rapid screening of potential drug candidates or probiotic formulations capable of restoring mucin integrity or selectively inhibiting pathogenic strains. This could revolutionize therapeutic paradigms for diseases like Crohn’s, where current treatments often involve systemic immunosuppression with substantial side effects. A precision-targeted microbial approach could offer safer, personalized interventions that address disease etiology at the microbial-host interface.

The joint BSF-NSF grant underpinning this research underscores the global importance of understanding IBD pathophysiology, and exemplifies the power of international collaboration in solving complex biomedical problems. It also highlights the growing relevance of synthetic biology tools in biomedical engineering—tools that transform biological phenomena into engineerable systems with diagnostic and therapeutic potential.

As research proceeds, the generation of the mucin-on-a-chip and subsequent experimental validation will serve not only as a model for IBD but may also be adapted to study other mucosal diseases where barrier integrity is compromised, including colorectal cancer and infectious enteropathies. This versatility makes the project a beacon of innovation with broad translational potential.

In summary, Dr. Ilana Kolodkin-Gal’s award-winning research marks a significant milestone towards understanding and combating inflammatory bowel diseases at a molecular and microbial level. By pioneering a mucin-on-a-chip platform, the study promises to unravel the intricate dialogue between invasive bacteria and the intestinal mucosal barrier, potentially transforming our approach to treating chronic gastrointestinal inflammation through precision synthetic biology and microbiome engineering.

Subject of Research: Investigating bacterial disruption of intestinal mucin integrity in inflammatory bowel disease through innovative mucin-on-a-chip technology.

Article Title: [Not provided]

News Publication Date: [Not provided]

Web References: [Not provided]

References: [Not provided]

Image Credits: [Not provided]

Keywords: Synthetic biology, inflammatory bowel disease, mucin, intestinal barrier, mucin-on-a-chip, Crohn’s disease, gastrointestinal microbiome, bioengineering, microbial interference, chronic inflammation

The mammalian gastrointestinal tract is a heavily immunocompetent organ, hosting an intricate network of immune cells finely tuned to balance tolerance and defense. Among these, T lymphocytes stand out for their antigen-specific surveillance and regulatory roles. Canonical T cells typically express either the CD4 or CD8αβ co-receptors, facilitating their well-characterized helper or cytotoxic functionalities. However, DNT cells defy this paradigm: they lack both CD4 and CD8αβ markers but express the T-cell receptor alpha-beta (TCRαβ), prompting questions about their lineage and immunological roles.

Led by Associate Professor Yasuhiro Nemoto and Professor Ryuichi Okamoto of the Institute of Science Tokyo, the research team focused on these double negative populations in the murine small intestine, leveraging advanced intravital imaging—a technique enabling real-time observation of cellular interactions within living organisms. This breakthrough allowed observation of DNT cells migrating autonomously through the intestinal lamina propria, an area densely populated by immune and epithelial cells.

Perhaps most startling was the elucidation of a novel immune function: DNT cells act as tolerogenic antigen-presenting cells. Traditionally, professional APCs such as dendritic cells, macrophages, and B cells capture and process antigens to prime naïve T cells, initiating adaptive immune responses. The discovery that DNT cells themselves internalize intestinal antigens and migrate to secondary lymphoid sites to present these antigens to naïve CD4⁺ T cells challenges existing immunological dogma. Unlike classical APCs, however, DNT cells conspicuously lack co-stimulatory molecules—such as CD80 and CD86—which are essential for the full activation of T cells.

This absence of co-stimulation imparts a critical functional twist. When DNT cells present antigens, they induce a state of anergy—or non-responsiveness—in CD4⁺ T cells rather than activation. Anergy is a fundamental mechanism to maintain immune tolerance and prevent aberrant inflammation. Thus, DNT cells act not as elicitors of immune attack but as regulators that suppress excessive immune responses, particularly in the immunologically complex environment of the gut where tolerance to dietary and commensal antigens must be preserved.

The physiological significance of these findings was underscored in murine models of intestinal inflammation. DNT cell activity correlated negatively with inflammation severity, supporting their role as anti-inflammatory mediators. More importantly, the team extended their observations to human disease, investigating samples derived from patients afflicted with Crohn’s disease, a chronic inflammatory condition of the gastrointestinal tract characterized by dysregulated immune responses. Here, DNT cells exhibited marked deficits in antigen uptake and presentation abilities, implying that impaired DNT cell function may contribute substantially to the pathogenesis of this debilitating disorder.

These insights open exciting new avenues in the pursuit of targeted immunotherapies for inflammatory bowel diseases (IBD). By harnessing or restoring the tolerogenic functions of DNT cells, therapeutic strategies could be designed to recalibrate intestinal immune responses, potentially offering relief and remission for patients suffering from Crohn’s disease and related disorders. This approach offers a stark contrast to broad-spectrum immunosuppressants currently in use, promising more precise modulation of immune pathways with fewer side effects.

The identification of DNT cells as a unique class of antigen-presenting cells also enriches the broader immunological framework by adding complexity to the cellular crosstalk within mucosal tissues. These findings underscore the dynamic plasticity of immune cells and suggest that immune cell specialization extends beyond traditional categorizations, particularly in tissue-specific contexts such as the gut.

Central to this discovery was intravital microscopy’s unparalleled ability to capture immune cell behavior in vivo. This technology combines advanced optics with sophisticated imaging software to permit longitudinal studies of cell motility, interaction, and function in their native microenvironment—insights impossible to glean from ex vivo or fixed samples. The visualization of DNT cell migration and antigen processing represents a methodological leap with broad applications across immunology.

Associate Professor Nemoto highlighted the novelty of the research, emphasizing the global first: “Our study is the inaugural report demonstrating that intestinal DNT cells serve as tolerogenic antigen-presenting cells. This challenges the longstanding paradigm that only classical APCs mediate antigen presentation and immune activation. The unique behavior of DNT cells positions them as key regulators of intestinal immune tolerance.”

Furthermore, the study suggests that immune regulation by DNT cells hinges not merely on antigen presentation but crucially depends on the absence of co-stimulation, delineating a mechanism by which these cells dampen inflammation rather than triggering it. This enhances our understanding of how immune tolerance is meticulously maintained in the gut despite constant exposure to foreign antigens.

Future directions include exploring the molecular signals governing DNT cell differentiation and antigen presentation, their interactions with other intestinal immune populations, and their potential alterations in various gastrointestinal diseases. Investigating ways to potentiate DNT cell regulatory functions or repair their dysfunction could revolutionize therapies for autoimmune and inflammatory conditions beyond Crohn’s disease.

In conclusion, the Institute of Science Tokyo’s landmark work not only elucidates a previously hidden facet of intestinal immunity but also paves the way for innovations in clinical immunology. The revelation that double negative T cells act as natural suppressors of intestinal inflammation, employing antigen presentation without activating co-stimulatory signals, provides a fresh blueprint for immunoregulatory mechanisms in the mucosa and highlights new therapeutic targets for inflammatory diseases. This study exemplifies the power of cutting-edge technology and collaborative science in unearthing the sophisticated balance of immune function within the human body.

Subject of Research: Animals

Article Title: Intestinal CD4−CD8αβ−TCRαβ+ T cells function as tolerogenic antigen presenting cells in mice

News Publication Date: 1-Aug-2025

Web References: https://doi.org/10.1038/s41467-025-62089-y

Image Credits: Institute of Science Tokyo

Keywords: Immune cells, Double negative T cells, Intestine, Antigen presentation, TCRαβ, Crohn’s disease, Intravital microscopy, Inflammatory bowel disease, Gut immunity, Tolerance, Anergy, Antigen-presenting cells